Lumos Diagnostics Holdings Ltd. · ASX:LDX

Lumos Diagnostics — Corporate Update (December 2023)

12 slides from Lumos Diagnostics's corporate update, Dec 6, 2023

  1. Slide 1: Commercial Operations Update

    Commercial Operations Update December 2023 www.lumosdiagnostics.com Confidential 1

  2. Slide 2: Disclaimer and Important Information

    Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “

  3. Slide 3: Commercial Update – US Launch of ViraDx and FebriDx

    Commercial Update – US Launch of ViraDx™ and FebriDx® AGENDA • Overview of Products • US Sales Channel Update • Production Update • ViraDx – US Commercial Update • FebriDx – US Commercial Update • Questions Confidential 3

  4. Slide 4: FebriDx – Lumos' POC test to aid antibiotic prescribing

    FebriDx – Lumos’ POC test to aid antibiotic prescribing • FebriDx is an aid for healthcare providers to improve patient care and antibiotic stewardship - FebriDx is a rapid, lateral flow, POC test that assists with differentiating between bacterial and non-bacterial infections - Very effective at ru

  5. Slide 5: ViraDx – Lumos' POC test for key respiratory infections

    ViraDx™ – Lumos’ POC test for key respiratory infections • ViraDx highly relevant POC test for post-pandemic environment: - SARS-CoV-2 pandemic increased consumer and healthcare POC testing - ViraDx is a 3-in-1 test for COVID-19/’flu A/’flu B - One of two tests available in market that provides visu

  6. Slide 6: Production

    Production • Commercialisation activities for FebriDx and ViraDx previously on hold: - Timing and likelihood of US regulatory clearances uncertain - Need to conserve cash reserves - Commenced commercial scale up activities in July 2023 • Established commercial production to meet initial anticipated

  7. Slide 7: Lumos' US Sales Channel

    Lumos’ US Sales Channel • Established low-cost, high-reach US sales channel: - Internal Commercial Operations Team: • Senior VP Commercial Operations, 4 direct reports - Eight Independent Commission-only sales representatives appointed - Distributors: • Over ten regional distributors appointed (Eg.

  8. Slide 8: ViraDx – US Commercial Update

    ViraDx – US Commercial Update • Positive market dynamics: - POC testing for respiratory infections well-established in US - CDC reporting harsh influenza season this year with outpatient respiratory illness continuing to track above baseline (season continues until March) • Sales of ViraDx in the US

  9. Slide 9: FebriDx – US Commercial Update

    FebriDx – US Commercial Update • Global threat of Antimicrobial Resistance (AMR) gaining attention: - World AMR Awareness Week just finished (18-24 Nov) - Recognised overprescribing of antibiotics one of the key drivers of AMR • On track for sales to commence by year end: - Pre-orders for FebriDx al

  10. Slide 10: FebriDx – US Commercial Launch Activities

    FebriDx – US Commercial Launch Activities • CLIA status: - Currently can be used in CLIA Moderately Complex Settings (10,000 labs) - Multiple paths to securing CLIA Waiver (260,000 clinical settings) • Reimbursement: - Two biomarker CPT codes identified – need to be tested - American Medical Associa

  11. Slide 11: US FebriDx Marketing Activities — Overview

    US FebriDx Marketing Activities — Overview Distributor Email Digital Press Strategic Product End User Sales calls Tradeshows Training campaigns advertising releases partnerships Education Onboarding Drip campaigns (through Regulatory Product Urgent Care Customer Product Presentations Salesforce) by

  12. Slide 12: Questions

    Questions © Lumos Diagnostics 2020, all rights reserved Confidential 12 Confidential 12

Lumos Diagnostics Holdings — Corporate Update (December 2023) on 6ix